SCHEMBL26211894

SCHEMBL26211894

CN(C)Cc1cccc(CC(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
ALDH1A1 P00352 2/20 0.52
AKR1B1 P15121 1/20 0.52
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
GLS O94925 1/20 0.48
NOS1 P29475 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
RGS12 O14924 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
NFKB1 P19838 1/20 0.44
APEX1 P27695 1/20 0.44
THPO P40225 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24060005 0.85 NOS1 (0.51) TSHRALDH1A1GLSNOS1MEN1
SCHEMBL26210116 0.84 AKR1B1 (0.47) TSHRALDH1A1AKR1B1CYP1A2CYP2C19
SCHEMBL70565 0.84 AKR1B1 (0.71) TSHRALDH1A1AKR1B1CYP1A2CYP2C19
SCHEMBL26732440 0.83 AKR1B1 (0.46) TSHRAKR1B1CYP1A2CYP2C19MEN1
SCHEMBL15042325 0.83 AKR1B1 (0.46) TSHRALDH1A1AKR1B1CYP1A2CYP2C19
SCHEMBL9871060 0.82 KEAP1 (0.55) TSHRALDH1A1NOS1KMT2A
Hydrochloric Acid SCHEMBL8922940 0.82 AKR1B1 (0.68) TSHRALDH1A1AKR1B1CYP1A2CYP2C19
SCHEMBL989636 0.82 ALDH1A1 (0.67) TSHRALDH1A1NOS1HPGDLMNA
SCHEMBL8785541 0.80 CA2 (0.56) TSHRALDH1A1AKR1B1KDM4EMAPT
SCHEMBL1515871 0.79 AKR1B1 (0.58) TSHRALDH1A1AKR1B1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS TSHR 2355/4885ALDH1A1 4236/4885AKR1B1 3777/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS TSHR 2355/4885ALDH1A1 4236/4885AKR1B1 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.